Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TEXAS MEDICAID VOLUME DRUG PURCHASING

Executive Summary

TEXAS MEDICAID VOLUME DRUG PURCHASING project will be monitored for effectiveness by the HHS Office of the Inspector General. According to the Inspector General's "Work Plan" for fiscal 1988-1989, which identifies and schedules projects for the period, the HHS office "will consider whether there could be significant savings if drugs were distributed through a revised system." Nothing that "recently revised Medicaid regulations offer considerable flexibility to the states in providing drugs to their recipients" ("The Pink Sheet" Aug. 3, p. 3), the work plan reports that "the state Medicaid agency in Texas has been exploring various alternatives to the present system for procuring drugs, including the purchase of drugs through state contracts with drug manufacturers and rebates based on volume utilization." Due to the "problems inherent in developing a program-wide alternative distribution system," the Inspector General's Audit Office "will consider whether there could be significant savings if drugs were distributed through a revised system." Physician dispensing will also be examined by the Inspector General's Office of Analysis & Inspections, according to the work plan. "This inspection will explore the implications of physician drug dispensing on patient care and health care financing programs, such as Medicaid," the plan states. "The study will provide an in-depth analysis of issues," the plan continues. Questions the study will explore include: "(1) whether the practice reduces the selection of drugs available to the physician for patient treatment or increases the number of office visits when a patient requires a drug refill, and (2) what benefits it has provided (for example, reduced travel time in rural areas)." The plan also describes a number of investigations to be undertaken by the Inspector General's Investigations Office. Several involve reports of pharmacies charging brandname prices for supplying generic drugs. Another investigation concerns a report that Medicaid billings by "a number of" Washington, D.C. drug stores "far exceed norms based on location and customer volume." The office is also investigating 21 California physicians "who allegedly are prescribing drugs for patients who do not medically require them."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS122308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel